Skip to content

Evaluation of a Dietary Supplement Containing Melissa Officinalis Formulated in Phospholipids on Mood Well-being and Cortisol Modulation

Pilot Study for the Evaluation of a Dietary Supplement Containing Melissa Officinalis Formulated in Phospholipids on Mood Well-being and Cortisol Modulation

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06942897
Enrollment
40
Registered
2025-04-24
Start date
2026-06-15
Completion date
2026-09-15
Last updated
2025-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Emotional Well-being, Mood Disorders, Stress

Brief summary

This is a randomized, double-blind, placebo-controlled pilot study designed to evaluate the effect of an oral nutritional supplement containing Melissa officinalis formulated in phospholipids on mood and cortisol levels in healthy adults. Participants will be randomly assigned to receive either the active supplement or a placebo daily for 3 weeks. The primary outcome measures include changes in mood well-being, perceived stress, and salivary cortisol levels. The study aims to assess both efficacy and safety of the supplement in modulating stress response and emotional balance.

Interventions

DIETARY_SUPPLEMENTMelissa officinalis supplement

This intervention consists of a standardized oral dietary supplement containing 400 mg of Melissa officinalis extract formulated in phospholipids. The supplement is administered once daily for 3 weeks to evaluate its potential effects on mood, stress perception, and cortisol levels in healthy adults.

Sponsors

Azienda di Servizi alla Persona di Pavia
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Age between 18 and 65 years * Healthy volunteers as assessed by medical history and physical examination * Willingness to comply with the study procedures

Exclusion criteria

* Current use of medications or supplements that may affect mood or cortisol levels * Known allergy or sensitivity to Melissa officinalis or phospholipids * History of psychiatric disorders (e.g., major depression, anxiety disorders) * Significant comorbidities (e.g., cardiovascular, hepatic, renal diseases) * Pregnant or breastfeeding women * Participation in another clinical trial in the past 30 days

Design outcomes

Primary

MeasureTime frameDescription
Change in perceived stress levels measured by the Perceived Stress Scale (PSS)week 4 (after 3 weeks of intervention)The PSS is a validated 10-item questionnaire that assesses the perception of stress over the past month. Scores range from 0 to 40, with higher scores indicating greater stress. The change from baseline to 3 weeks will be measured.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026